trending Market Intelligence /marketintelligence/en/news-insights/trending/h0EIHYahjYVI9G9kWY0vAw2 content esgSubNav
In This List

ReShape Lifesciences buys Apollo Endosurgery's gastric surgery products for $17M

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


ReShape Lifesciences buys Apollo Endosurgery's gastric surgery products for $17M

ReShape Lifesciences Inc. has purchased Apollo Endosurgery Inc.'s surgical product line, which includes an adjustable gastric band surgically installed around the stomach for weight loss, in a cash transaction of $17 million.

ReShape Lifesciences made an up-front payment of $10 million and also gave Apollo its intragastric balloon product line, which are inflatable medical devices placed into the stomach when diet and exercise have failed and surgery is not an option.

The remaining amount will be paid to Austin, Texas-based Apollo Endosurgery in yearly installments. Apollo Endosurgery will have the legal right to get back its surgical product line until San Clemente, Calif.-based ReShape Lifesciences either makes the full payment or raises $15 million through a qualified offering.

ReShape Lifesciences develops devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders.

Cooley LLP was legal adviser to Apollo Endosurgery for the transaction, which closed Dec. 17.